Overall, a 20% decrease in LDL cholesterol was seen. Participants reported that they would have found more information on drug interactions ... make statins unavailable to non-insured or indigent ...

AstraZeneca has bought rights to an orally-active drug that inhibits ... which in February became the first non-statin, orally-active medication to lower cholesterol that the FDA has approved ...

4, 2024 — In addition to lowering your cholesterol ... put them at risk for cardiovascular disease, a new ... Common Hair Loss and Prostate Drug May Also Cut Heart Disease Risk in Men and ...

Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented ... who cannot tolerate statins or who cannot reach ...

So, an elevated LDL cholesterol level is a major risk factor for heart disease and stroke. While lowering LDL cholesterol levels with statin drugs significantly reduces cardiac risk, reducing LDL ...

Other outcomes may also be relevant, for example, non-fatal cardiovascular ... net benefit of the drug, such as the CI of the HR, into a postponement model. Consequently, there are currently no ...

The third Adult Treatment Panel of the National Cholesterol ... drug in the lowering of LDL-C; however, HDL-C change did not differ significantly among the different statins. Non-HDL-C was ...

Child care, housing costs and public safety were the New York governor’s top issues as she outlined her policy plans for the year and for a re-election fight in 2026. By Maya KingBenjamin ...

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public ...

is a commercial stage biopharmaceutical company focused on bringing new medicines to market ... once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are ...

Jan. 2, 2025 — One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new study suggests.

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods gained and the significance of the new drugs and biologics that these ...